September 7, 2022 by Chain Drug Review
Aurigene Pharmaceutical Services Limited, Dr. Reddy's Laboratories
Pharmacy, Supplier News
HYDERABAD, India — Dr. Reddy’s and Aurigene Pharmaceutical Services Limited, a contract research, development and manufacturing services organization and fully owned stepdown subsidiary of Dr. Reddy’s announce a Memorandum of Understanding (MoU) with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization that develops new therapeutic solutions for neglected diseases and
August 24, 2022 by Chain Drug Review
Dr. Reddy's Laboratories
Supplier News
PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the first-to-market launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). “The launch of Dr. Reddy’s Fexofenadine HCl 180
April 11, 2022 by Chain Drug Review
Dr. Reddy's Laboratories, SOLU-MEDROL brand
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s announced the launch of methylprednisolone sodium succinate for injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA). The SOLU-MEDROL brand and generic had U.S. sales of approximately $144 million MAT for the most recent
February 22, 2022 by Chain Drug Review
Dr. Reddy's Laboratories
February 21, 2022, Pharmacy, Supplier News
PRINCETON, N.J. — North American generics is Dr. Reddy’s largest market — in fiscal 2021, it contributed nearly $1 billion, representing a growth of 9% over the previous year and around 46% of the company’s gross generics sales; and 37% of overall sales. The introduction of new SKUs has helped to accelerate that growth. In
December 7, 2021 by Chain Drug Review
Dr. Reddy's Laboratories
December 6, 2021, Pharmacy
Vincent Colicchio is vice president of supply chain and external manufacturing for Dr. Reddy’s Laboratories North America. In this interview he discusses optimizing the industry’s workforce, facilities and processes, including measures to avoid drug shortages. CDR: What do you see as workforce needs and training for generic drug manufacturing? COLICCHIO: For generic drug manufacturing, there
October 29, 2021 by Chain Drug Review
Dr. Reddy's Laboratories
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration. The Akovaz brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent
September 2, 2021 by Chain Drug Review
Dr. Reddy's Laboratories
Pharmacy, Supplier News
MISSISSAUGA, Ontario — Dr. Reddy’s Laboratories today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. “Our launch of Reddy-Lenalidomide represents our firm commitment to providing
September 23, 2020 by Chain Drug Review
Dr. Reddy's Laboratories, G.V. Prasad
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s path to excelling in the manufacture of complex generics and biosimilars depends on its successful filing for new drugs — be these formulations or active pharmaceutical ingredients (APIs). In fiscal 2020, the company filed eight new Abbreviated New Drug Applications (ANDAs) with the Food and Drug Administration. As of March
August 12, 2020 by Chain Drug Review
ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, Dr. Reddy's Laboratories, Marc Kikuchi
Pharmacy, Supplier News
PRINCETON, N.J. – Dr. Reddy’s announced the launch of ciprofloxacin 0.3% and dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring
July 28, 2020 by Chain Drug Review
Dr. Reddy's Laboratories, Vanessa Brill
July 27, 2020, Pharmacy
PRINCETON, N.J. — When the COVID-19 pandemic hit, the generic drug industry faced many challenges, says Vanessa Brill, vice president and regional general counsel for the Americas at Dr. Reddy’s Laboratories. For Dr. Reddy’s, the challenges included finding ways to continue to produce drugs at manufacturing facilities that had to operate at decreased capacity out
June 13, 2020 by Chain Drug Review
COVID-19, Dr. Reddy's Laboratories, Gilead Sciences, Remdesivir
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this
May 7, 2020 by Chain Drug Review
Dr. Reddy's Laboratories, elyxb, Erez Israeli
Pharmacy, Supplier News
PRINCETON, N.J. —Dr. Reddy’s announced approval of Elyxyb (celecoxib oral solution 25 mg/mL) by the U.S. Food and Drug Administration (USFDA). Elyxyb (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. Elyxyb is the latest product emerging from Dr. Reddy’s portfolio of successful acute migraine treatments.
May 7, 2020 by Chain Drug Review
4 mcg/mL Single-dose Ampules, desmopressin acetate injection USP, Dr. Reddy's Laboratories, Marc Kikuchi
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s announced the launch of desmopressin acetate injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9
March 23, 2020 by Chain Drug Review
2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, Dr. Reddy's Laboratories, Marc Kikuchi, Naloxone Hydrochloride Injection USP
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s Laboratories announced Monday the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring our second product to market that has been
